drugset / Trial / NCT06518122

A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers

NCT06518122

Phase 1 Completed 66 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug-drug interaction and safety between HCP1306, RLD2302 and RLD2102 in healthy volunteers.

Timeline

Start
2024-09-01
Primary completion
2025-01-03
Completion
2025-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1306 Unknown
Subject RLD2102 Unknown
Subject RLD2302 Unknown

Indications

No indication recorded.